Multinational Pharma Giants Forge Strategic Alliances with Chinese Biotechs in Early 2026, Signaling a New Era of Global Collaboration

　　【Pharmaceutical Network Industry Dynamics] Just two months into 2026, the pharmaceuticals industry has already seen a surge in collaborations between Chinese pharmaceutical companies and multinational corporations. Overall, these partnerships have evolved from single-product licensing to comprehensive, long-term strategic ecosystem alliances spanning the entire industrial chain. Moreover, cooperation is no longer limited to the R&D sector but has also extended to areas such as production, showcasing a trend of diversified development.
 

On February 8, Innovent Bio announced that it had reached a strategic collaboration with Eli Lilly on innovative drug development. Both parties will jointly advance the global development of innovative drugs in the fields of oncology and immunology. According to the agreement terms, Innovent Bio will directly receive an upfront payment of $350 million. Additionally, upon reaching multiple milestones related to research and development, regulatory progress, and commercialization, Innovent is eligible to receive milestone payments totaling up to approximately $8.5 billion, as well as tiered sales royalties for relevant products in markets outside of Greater China.
 

Notably, this strategic cooperation marks the seventh collaboration between Innovent Bio and Eli Lilly. As early as 2015, the two parties signed a milestone agreement regarding PD-1 monoclonal antibodies and multiple oncology antibody drugs. Through numerous collaborations, they have established a stable and efficient collaboration mechanism in project screening, decision-making pace, and global clinical advancement.
 

On February 5, Fosun Pharma announced that its controlled subsidiary, Shanghai Henlius Biotech, Inc., had signed a "License Agreement" with Eisai Co., Ltd. Henlius granted Eisai the rights to develop, manufacture, and commercialize serplulimab injection for tumor indications treatment within the Japan region.
 

The agreement shows that Eisai will pay Shanghai Henlius Biotech, Inc. up to 155 million US dollars in non-refundable upfront and regulatory milestone payments. Among them, the upfront payment is 75 million US dollars, and the regulatory milestone payment is up to 80.01 million US dollars. In addition, Eisai will also pay up to 233 million US dollars in sales milestone payments.
 

On February 3, PepLib announced that it had reached a global R&D collaboration and licensing agreement with Eli Lilly to jointly advance the development of novel peptide candidate drugs. This marks another significant international breakthrough for the company in a short period, following a global licensing agreement with Novartis in January this year.
 

According to the agreement, PepLib will be responsible for screening and identifying the optimal peptide active molecules for the collaborative projects based on its own platform, and will receive an upfront payment and other near-term payments, as well as being entitled to subsequent development, regulatory, and sales milestone payments. Lilly will be responsible for the subsequent drug's IND application research, clinical development, and commercialization.
 

On February 2, SANEGENEBIO announced a global research and development collaboration and licensing agreement with Genentech (a subsidiary of Roche Group). Both parties will jointly advance the development of an RNAi therapy based on SANEGENEBIO's proprietary RNAi drug discovery platform. Under the terms of the agreement, SANEGENEBIO will receive an upfront payment of $200 million and is eligible to receive development and sales milestone payments totaling $1.5 billion, as well as tiered royalties.
 

The agreement shows that SANEGENEBIO will grant Genentech the global exclusive rights for the development and commercialization of the drug. SANEGENEBIO will be responsible for the early-stage research and development of the drug, while Genentech will handle all subsequent clinical development and commercialization activities. This marks another licensing collaboration reached by SANEGENEBIO in the past three months. On November 8, 2025, SANEGENEBIO announced a global R&D collaboration and licensing agreement worth up to $1.5 billion with Eli Lilly and Company. Both parties will jointly advance the development of RNAi candidate drugs targeting metabolic diseases based on SANEGENEBIO’s proprietary LEAD™ platform.
 

　　……
 

Overall, the wave of cooperation in early 2026 reflects that China's pharmaceutical innovation has entered the global value realization phase. The value of technology platforms has gained international recognition, and the cooperation model has shifted from passive licensing to active co-construction, marking a new stage. For Chinese pharmaceutical companies, it is essential to continue strengthening technological originality, deepen international cooperation, and accelerate the strategic upgrade from "Chinese innovation" to "global innovation" to further enhance market competitiveness and drive the high-quality development transformation of China’s pharmaceutical industry.
 

　Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.